A patient with systemic lupus erythematosus and lupus nephritis: the potentials for biological therapy
- 作者: Damyanov N.1, Vinogradova I.B.2, Bezgin A.V.3, Knyazeva L.A.4
-
隶属关系:
- University of Belgrade
- Ulyanovsk Regional Clinical Hospital
- Kursk Regional Clinical Hospital
- OOO Medical Center № 1, Kursk
- 期: 卷 13, 编号 3 (2021)
- 页面: 44-48
- 栏目: Articles
- URL: https://journals.eco-vector.com/2075-3594/article/view/273785
- DOI: https://doi.org/10.18565/nephrology.2021.3.44-48
- ID: 273785
如何引用文章
详细
全文:
作者简介
Nemanja Damyanov
University of Belgrade
Email: nemanjadamjanov@yahoo.com
Dr.Sci. (Med.), Professor, Head of the Department of Rheumatology, Faculty of Medicine
Irina Vinogradova
Ulyanovsk Regional Clinical Hospital
Email: kazvin@yandex.ru
Cand. Sci. (Med.), Head of the Department of Rheumatology
Artem Bezgin
Kursk Regional Clinical Hospital
Email: bezgin_artem@inbox.ru
Dr. Sci. (Med.), Nephrologist, Department of Nephrology
Larisa Knyazeva
OOO Medical Center № 1, Kursk
Email: larisa.x.kniazeva@gsk.com
Dr. Sci. (Med.), Professor, Head of the Department of Rheumatology
参考
- Kaul A., Gordon C., Crow M.K., et al. Systemic lupus erythematosus. Nat. Rev. Dis. Primers. 2016;2:16039. doi: 10.1038/nrdp.2016.39.
- Tsokos G.C., Lo M.S., Costa Reis P., Sullivan K.E. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat. Rev. Rheumatol. 2016;12(12):716-730. doi: 10.1038/nrrheum.
- Rekvig O.P. Autoimmunity and SLE: Factual and semantic evidence-based critical analyses of definitions, etiology, and pathogenesis. Front. Immunol. 2020;11:569234. doi: 10.3389/fimmu.2020.569234.
- Mahajan A., Amelio J. Gairy K., et al. Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression. Lupus. 2020;29:1011-1020.
- Hanly J.G., et al. The frequency and outcome of lupus nephritis: resultsfrom an international inception cohort study. Rheumatol. 2016;55:252-262.
- Piga M., Arnaud L. The main challenges in systemic lupus erythematosus: Where do we stand? J. Clin. Med. 2021;10(2):243. doi: 10.3390/jcm10020243.
- Lockshin M.D., Barbhaiya M., Izmirly P., et al. SLE: Reconciling heterogeneity. Lupus Sci. Med. 2019;6(1):280. doi: 10.1136/lupus-2018-000280.
- Lo M.S., Tsokos G.C. Recent developments in systemic lupus erythematosus pathogenesis and applications for therapy. Curr. Opin. Rheumatol. 2018;30(2):222-228. doi: 10.1097/BOR.0000000000.
- Furie R., Rovin B.H., Houssiau F., et al. Two-Year, Randomized, controlled trial of Belimumab in lupus nephritis. N. Engl. J. Med. 2020;383(12):1117-1128. doi: 10.1056/NEJMoa2001180.
- Cassese G., Lindenau S., de Boer B., et al. Inflamed kidneys of NZB/W. mice are a major site for the homeostasis of plasma cells. Eur. J. Immunol. 2001;31:2726-2732.
- Chang A., Henderson S.G., Brandt D., et al. In situ B. cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis. J. Immunol. 2011;1861849-1860.
- Clark M.R., Trotter K., Chang A. The pathogenesis and therapeutic implications of tubulointerstitial inflammation in human lupus nephritis. Semin. Nephrol. 2015;35:455-464.
- Allen M.E., Rus V., Szeto G.L. Leveraging Heterogeneity in Systemic Lupus Erythematosus for New Therapies. Trends Mol. Med. 2021;2(2):152-171.
- Benlysta prescribing information. Research Triangle Park, NC: GlaxoSmith Kline, 2019. https://www.accessdatafda.gov/drugsatfda_docs/label/2019/125370s067,761043s005lbl.pdf.
- Dooley M.A., Houssiau F., Aranow C., et al. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus 2013;22:63-72.
- Furie R., Rovin B.H., Houssiau F., et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N. Engl. J. Med. 2020;383:1117-1128. doi: 10.1136/annrheumdis-2020-216924.
- Российские клинические рекомендации «Ревматология». Под ред. Е.Л. Насонова. М., 2020. 132 с.